SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies (OPEN) is currently trending due to recent announcements aimed at significantly lowering mortgage rates and boosting the broader housing market. This news has ignited strong community optimism, with many anticipating a substantial increase in transaction volume and a potential short squeeze for the real estate technology stock. Despite ongoing discussions about company fundamentals and potential warrant dilution, a prevailing bullish sentiment suggests a significant upside for OPEN within the revitalized housing sector.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is capturing significant attention following recent industry developments, notably Marvell's acquisition of a key partner and Nvidia's increased emphasis on photonics for advanced AI infrastructure. The community is actively discussing POET's unique optical interposer platform, which promises disruptive advancements in speed, cost, and power efficiency for next-generation data centers, fueling high anticipation for forthcoming commercialization milestones and strategic orders.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The controversial ICE agent-involved shooting in Minneapolis is a dominant discussion point for $DJT, with community members sharply divided over the justification of force and characterizing the event as either murder or a necessary act of self-defense. Amidst this, users are also actively debating recent statements from Donald Trump regarding potential housing market interventions, including instructing representatives to consider buying $200 billion in mortgage bonds and restricting institutional homeownership, with some critics drawing comparisons to "democratic socialist" policies.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is generating significant community buzz, primarily driven by strong anticipation for a multi-billion dollar NASA Lunar Terrain Vehicle (LTV) contract award. Investors are also noting a recently identified federal contract with NASA and the strategic Lanternis acquisition, positioning LUNR as a key player in the expanding aerospace and defense sector. This widespread bullish sentiment is fueled by expectations of a substantial price surge upon the LTV announcement, with many observing increased short activity.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is currently facing heightened market uncertainty, as investors closely monitor the anticipated Supreme Court ruling on tariffs and upcoming economic data, including the jobs report. Community sentiment is sharply divided, with some anticipating new highs while others express concern about Nasdaq losing momentum and potential market manipulation amidst broader geopolitical and political policy shifts.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is trending due to robust year-over-year growth in its latest sales report and escalating demand for AI chips, prompting major investment banks to raise price targets. The community is actively discussing TSM's critical role as the global "backbone" for advanced AI semiconductor manufacturing. This strong position is further underscored by reports that NVIDIA is seeking increased H200 production, despite ongoing geopolitical considerations regarding Taiwan.

Polygon

Polygon is actively trending amid significant discussion surrounding its utility and institutional adoption, with reports of BlackRock investments and J.P. Morgan leveraging its DeFi capabilities, alongside integrations with platforms like Instagram. The community is eagerly debating a potential return to the familiar MATIC ticker, balancing Polygon's ongoing technical advancements as a leading Ethereum Layer 2 solution with strong brand recognition. This confluence of major partnerships and an internal brand identity discussion is fueling widespread conversation.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following disappointing FY2026/2027 revenue guidance for its key drug, DefenCath, amidst the anticipated expiration of a crucial reimbursement mechanism, triggering widespread community frustration and a significant stock sell-off. While management highlights portfolio diversification and pipeline catalysts, investors are intensely debating the stock's valuation and the potential impact of pending legislation aimed at improving kidney care payment systems.

Pippin is an SVG unicorn drawn using the latest LLM benchmarks on ChatGPT 4o. It is an autonomous AI agent on X. Pippin was created by Yohei Nakajima, a recognised innovator and thought leader in the Al VC space (followed by Jeff Bezos and Marc Andreessen). He is known for his build-in-public approach and has been at the forefront of the ‘AI for VC’ movement, launching over 100+ AI-driven prototypes, automation agents &amp; open-source projects.  His most notable build is BabyAGI (March 2023), the first popular open-source autonomous agent with task-planning capability. The project went viral on Twitter amassing millions of impressions and resulting in tens of thousands of GitHub stars, dozens of Arxiv citations, coverage across major online media publications globally, and many speaker engagements including the inaugural TED AI in San Francisco.

pippin

PIPPIN CRYPTO is trending due to significant price surges, reportedly fueled by short squeezes and recent exchange listings for this Solana-based, AI-driven project. Community sentiment is sharply divided, with many celebrating its strong performance and resilience, while a vocal segment warns of it being a potential scam, citing concerns over concentrated whale holdings and manipulated volume.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The stock rose after a sharp selloff earlier in the session tied to cautious 2026 guidance.</li><li>Analysts flagged a steeper-than-expected slowdown in DefenCath revenue.</li><li>A new CEO employment agreement appeared to help steady investor sentiment following the drop.</li></ul>Shares of CorMedix Therapeutics rose in after-hours trading on Thursday after the company disclosed an expanded role and revised employment terms for CEO Joseph Todisco, following a sharp selloff earlier in the session tied to cautious guidance.The stock climbed nearly 1% in after-hours trading on Thursday after crashing 33% in the regular session to log its worst session in over three years.&nbsp;<h2 class="st-heading-2">CEO Elevated To Chairman With Pay Boost</h2>CorMedix said it entered into an amended and restated employment agreement with Todisco on Monday. Under the agreement, Todisco will continue as CEO and will also serve as chairman of the board, effective Thursday.&nbsp;Todisco’s annual base salary increases to $750,000 from $665,000, effective Jan. 1. His target annual bonus opportunity rises to 75% of base salary from 65%, beginning with fiscal 2026, with payouts based on company and individual objectives set by the board or its compensation committee. He remains eligible for equity awards under the company’s omnibus stock incentive plan as well.&nbsp;<h2 class="st-heading-2">Rich Exit Terms Kick In Under New CEO Deal</h2>If terminated without cause or for good reason, and subject to a customary release, Todisco would receive 18 months of base salary continuation, a prorated annual bonus based on actual performance, subsidized Consolidated Omnibus Budget Reconciliation Act (COBRA) premiums for up to 18 months, acceleration of certain near-term unvested equity awards, and any unpaid prior-year bonus.&nbsp;If termination occurs within 24 months of a corporate transaction, severance increases to 200% of base salary plus target bonus paid over 24 months, COBRA subsidies extend to 24 months, and all unvested equity awards fully accelerate.&nbsp;<h2 class="st-heading-2">DefenCath Reality Check</h2>On Thursday, CorMedix&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-crmd-stock-crash-28-today/cmUbayOR45b">issued a cautious 2026 outlook</a>, warning revenue could come in below 2025 levels. Following the outlook, Truist Securities lowered its price target to $16 from $20 while maintaining a ‘Buy’ rating, noting that 2026 revenue guidance was roughly 40% below Street expectations and that 2027 DefenCath revenue guidance was about half of its initial estimate.&nbsp;Truist said this implied a greater tail-off in DefenCath revenue than previously factored and added it expects more detail at the company’s Feb. 10 investor day.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CorMedix was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/crmd_ss_png_5aaf19cbd0.webp" alt="crmd ss.png" width="968" height="144"><figcaption>TSLA sentiment and message volume as of January 8| Source: Stocktwits</figcaption></figure>One user said they bought 1,000 shares at $7.42, viewed the stock as oversold despite positive cash flow, and planned to sell above $8.<stembedurl>https://stocktwits.com/DSL12345/message/641298854</stembedurl>Another user noted that price targets remain above $15 and that the stock is currently trading at a 50% discount.<stembedurl>https://stocktwits.com/coveredcall123/message/641298735</stembedurl><a href="https://stocktwits.com/symbol/CRMD">CorMedix’s stock</a> has declined 31% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the CorMedix logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CorMedix Stock Rises After-Hours: CEO Locks In Chairman Seat, Bigger Paycheck And Rich Severance

Joseph Todisco’s annual base salary increases to $750,000 from $665,000, effective Jan. 1.

Equity

CorMedix's (CRMD) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated a "buy" rating and set a $14.00 price objective on shares of CorMedix in a research note on Thursday...

GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies

GSK's bepirovirsen hit primary endpoints in two phase III trials, boosting hopes for a functional cure in chronic hepatitis B patients.

CNC Deepens Medicaid Strategy With Cityblock Partnership in Illinois

Centene expands its Medicaid strategy by partnering with Cityblock Health to serve 10,000 Illinois members with 24/7 wrap-around care.

CorMedix (NASDAQ:CRMD) Shares Gap Down - What's Next?

CorMedix (NASDAQ:CRMD) Shares Gap Down - Time to Sell...

GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug

Monte Rosa shares surge 45% after interim phase I data show that MRT-8102 drives deep NEK7 degradation and reduces sharp inflammation markers.

<ul class="summary-bullets"><li>The outlook includes $150 million to $170 million from DefenCath, with results weighted toward the first half of the year.</li><li>The company expects adjusted EBITDA for 2026 to be between $100 million and $125 million.</li><li>CorMedix is commercializing a portfolio of anti-infective products.</li></ul>Shares of CorMedix Therapeutics (CRMD) plunged 28% on Thursday after the company issued a cautious full-year 2026 outlook, signalling revenue could come in below 2025 levels.<a href="https://stocktwits.com/symbol/CRMD">CRMD</a> was among the top trending stocks at the time of writing.CorMedix posted net revenue of around $127 million in the fourth quarter (Q4) of 2025 and $310 million for the full year, with pro forma full-year revenue of about $400 million. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) for Q4 is expected to range between $77 million and $81 million.<h2 class="st-heading-2">Full-Year Expectations</h2>For 2026, CorMedix expects revenue between $300 million and $320 million, including $150 million to $170 million from DefenCath, with performance weighted toward the first half of the year. DefenCath is an FDA-approved catheter lock solution used to reduce bloodstream infections in certain adult dialysis patients with central venous catheters.Adjusted EBITDA for 2026 is projected at $100 million to $125 million, supported by $35 million in annualized cost synergies from the Melinta acquisition. Last August, CorMedix acquired Melinta Therapeutics in a $300 million deal, which also includes up to $25 million in regulatory milestone payments and royalties.<h2 class="st-heading-2">Key Updates</h2>Commercial momentum continues to be driven by DefenCath, which is seeing strong utilization and patient growth among outpatient dialysis customers. CorMedix noted that reimbursement for DefenCath will decline in the second half of 2026 as the Transitional Drug Add-on Payment Adjustment&nbsp;(TDAPA) transitions to a post-TDAPA add-on adjustment, pressuring pricing later in the year.However, the company expects reimbursement to improve in 2027, potentially supporting higher pricing compared to late 2026.On the clinical front, Phase 3 data from the ReSPECT study of REZZAYO antifungal medication is expected in Q2 2026, while enrollment continues in a Phase 3 study of DefenCath in total parenteral nutrition (TPN) patients. CorMedix is also commercializing a portfolio of anti-infective products.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the sharp intraday decline, retail sentiment on Stocktwits flipped to ‘bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes. CRMD was among the top trending tickers on the platform.<img src="https://news.stocktwits-cdn.com/CRMD_jpg_84acb69cec.webp" alt="CRMD.jpg">One user questioned the company’s financial outlook.<stembedurl>https://stocktwits.com/Spoonorama/message/641198820</stembedurl>Another user sounded skeptical about the company’s second-half performance.<stembedurl>https://stocktwits.com/Brunoez/message/641203929</stembedurl>Over the past year, the stock has declined about 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mltx-stock-jump-45-in-pre-market-today/cmUbJFWR4Pt">Why Did MLTX Stock Jump 45% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did CRMD Stock Crash 28% Today?

CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.

KRYS Stock Surges 57% in a Year: More Upside Potential in 2026?

Shares of Krystal Biotech soar 57% in a year as strong Vyjuvek uptake and steady pipeline progress continue to push the stock higher.

EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study

Exelixis teamed with Natera on the phase III STELLAR-316 study testing zanzalintinib in resected stage II/III colorectal cancer. Stock gains. 



Select Medical Expands Rehab Footprint Through Vibra Healthcare JV

SEM teams up with Vibra Healthcare to run a 76-bed rehab hospital in Southern Kentucky, expanding its post-acute care footprint through a capital-efficient JV.

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Stocktwits

Stocktwits Polls

Traders are in shock as new guidance confirms a significant revenue drop for DefenCath following the end of TDAPA funding in mid-2026, leading to massive sell-offs.

CEO Joe Todisco faces intense criticism for the unexpected low revenue guidance, alleged manipulation, and receiving a pay raise amid the stock's plummet.

Many investors are viewing the drastic price drop as a prime "buy the dip" opportunity, citing the company's underlying value and potential rebound.

Despite current setbacks, community members hold onto hope for an upcoming legislative bill (S.2730) and future pipeline catalysts like REZZAYO and TPN approval.

CRMD
CorMedix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRMD News

CRMDCorMedix Inc